Boehringer Ingelheim Pharmaceuticals‘s Cyltezo, a second biosimilar for AbbVie’s Humira, received FDA approval.
AzurRx BioPharma enrolled a sixth patient into its phase IIa trial for MS1819, a treatment for exocrine pancreatic insufficiency associated with chronic pancreatitis.
4D Pharma is preparing to move its irritable bowel syndrome drug, Blautix, into a phase II clinical trial.
More articles on gastroenterology:
Stock market week-in-review for 5 large GI companies — Aug. 21-25
GI center to know: Associated Endoscopy
GI leader to know: Dr. G. Whit James of Associates in Gastroenterology
